8月22日 - ** 制药商 Biohaven BHVN.N股价盘前上涨 9.2% 至 16.03 美元
** 文件显示，美国FDA已告知Biohaven，原计划召开的咨询委员会会议不再需要用于决策。 (link)
** 今年 5 月，FDA 延长了 (link) 遗传病药物曲利卢唑上市申请的审查期。
** 预计卫生监管机构仍将在 2025 年第四季度做出决定
** 该公司正在测试曲利卢唑，用于治疗患有脊髓小脑共济失调症的成年患者，这是一种影响运动和平衡的罕见疾病，目前还没有获得 FDA 批准的治疗方法。
** 股价今年以来下跌了 60
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.